Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis
Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis
This Competitive Intelligence Report about VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) used to treat various cancers and ophthalmic diseases as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The family of antibody products targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) has become highly successful in clinical and economic terms. Avastin and Lucentis as the first generation products and Eylea and Zaltrap as the second wave of VEGF products followed by the anti-VEGF-R2 antibody Cyramzy generated combined product sales of more than US$ 13.7 bln in the year 2014. Strong driver of sales growth are the pipelines in a product leading to approval in more and more cancer and eye disease indications.
The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation „biobetter or biosuperior“ molecules as well as of biosimilar copies of the originator products with the most advanced molecules already in phase III trials.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence Report about VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) used to treat various cancers and ophthalmic diseases as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The family of antibody products targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) has become highly successful in clinical and economic terms. Avastin and Lucentis as the first generation products and Eylea and Zaltrap as the second wave of VEGF products followed by the anti-VEGF-R2 antibody Cyramzy generated combined product sales of more than US$ 13.7 bln in the year 2014. Strong driver of sales growth are the pipelines in a product leading to approval in more and more cancer and eye disease indications.
The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation „biobetter or biosuperior“ molecules as well as of biosimilar copies of the originator products with the most advanced molecules already in phase III trials.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) Marketed VEGF & VEGF-R Antibodies in Oncology:
Avastin Sales & Pipeline
Zaltrap Sales & Pipeline
Cyramza Sales & Pipeline
2) Avastin & Zaltrap Biosuperiors:
Anti-VEGF Pipeline in Oncology
Bispecific Anti-VEGF & Antibody Combination Antibody Pipeline in Oncolgy
3) Cyramza Biosuperiors:
Anti-VEGF-R & Antibody Combination Pipeline
Bispecific Anti-VEGF-R Antibody Pipeline
4) Avastin Biosimilar Pipeline
5) Marketed VEGF Antibodies in Ophthalmology
Lucentis Sales & Pipeline
Eylea Sales & Pipeline
6) Biosuperior Lucentis & Eylea Pipeline:
Anti-VEGF Antibody Pipeline in Ophthalmology
Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
7) Lucentis Biosimilar Pipeline
8) Corporate VEGF and VEGF-R Antibody Biosimilar & Biosuperior Pipelines
Avastin Sales & Pipeline
Zaltrap Sales & Pipeline
Cyramza Sales & Pipeline
2) Avastin & Zaltrap Biosuperiors:
Anti-VEGF Pipeline in Oncology
Bispecific Anti-VEGF & Antibody Combination Antibody Pipeline in Oncolgy
3) Cyramza Biosuperiors:
Anti-VEGF-R & Antibody Combination Pipeline
Bispecific Anti-VEGF-R Antibody Pipeline
4) Avastin Biosimilar Pipeline
5) Marketed VEGF Antibodies in Ophthalmology
Lucentis Sales & Pipeline
Eylea Sales & Pipeline
6) Biosuperior Lucentis & Eylea Pipeline:
Anti-VEGF Antibody Pipeline in Ophthalmology
Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
7) Lucentis Biosimilar Pipeline
8) Corporate VEGF and VEGF-R Antibody Biosimilar & Biosuperior Pipelines
